Back to results
US 4,059,641 AGranted
Polyprenyl derivatives
AssigneeSankyo Company, Limited
InventorsHiroshi Mishima, Akira Ogiso, Shinsaku Kobayashi
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeSankyo Company, Limited
InventorsHiroshi Mishima, Akira Ogiso, Shinsaku Kobayashi
Estimating the term…
Polyprenyl derivatives having the formula ##STR1## in which R.sup.1 and R.sup.2 may be the same or different and each represents hydrogen atom, hydroxyl group, an alkoxy group having 1-8 carbon atoms, an aliphatic acyloxy group having 2-18 carbon atoms, an aromatic acyloxy group or an araliphatic acyloxy group having 2-3 carbon atoms in the aliphatic acyl moiety, R.sup.3 represents hydrogen atom, an alkyl group having 1-8 carbon atoms, an aliphatic acyl group having 2-18 carbon atoms, an aromatic acyl group or an araliphatic acyl group having 2-3 carbon atoms in the aliphatic acyl moiety, n is an integer of 1-4 and, when n is an integer of 2-4, R.sup.2 's may be the same or different; provided that, when n is 1 or 2, at least one of R.sup.1 and R.sup.2 's is hydroxyl group, an alkoxy group, an aliphatic acyloxy group, an aromatic acyloxy group or an araliphatic acyloxy group. These derivatives are useful as medicines for treating peptic ulcer.
A compound having the formula ##STR20## in which R.sup.1 and R.sup.2 may be the same or different and each represents a hydrogen atom or a hydroxyl group, R.sup.3 represents a hydrogen atom, n is an integer of 1-4 provided at least one of R.sup.1 and R.sup.2 is a hydroxyl group, said compound being in substantially pure form.
7-Hydroxymethyl-3,11-dimethyl-2,6,10-dodecatrien-1-ol, said compound being in substantially pure form.
7-Hydroxymethyl-3,11,15-trimethyl-2,6,10,14-hexadecatetraen-1-ol, said compound being in substantilly pure form.
11-Hydroxymethyl-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-ol, said compound being in substantially pure form.
7,15-Dihydroxymethyl-3,11-dimethyl-2,6,10,14-hexadecatetraen-1-ol, said compound being in substantially pure form.
7-Hydroxymethyl-3,11,15,19-tetramethyl-2,6,10,14,18-eicosapentaen-1-ol, said compound being in substantially pure form.
(E,Z,E), (E,E,E), (Z,E,E), (E,Z,Z), (E,E,Z) and (Z,Z,E)-7-Hydroxymethyl-3,11,15-trimethyl-2,6,10,14-hexadecatetraen-1-ol, said compound being in substantially pure form.
(E,E,E), (E,Z,E), (E,E,Z) and (E,Z,Z)-11-Hydroxymethyl-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-ol, said compound being in substantially pure form.
(E,Z) and (E,E)-7-Hydroxymethyl-3,11-dimethyl-2,6,10-dodecatrien-1-ol, said compound being in substantially pure form.
(E,Z,E,E) and (E,E,E,E)-7,15-Dihydroxymethyl-3,11-dimethyl-2,6,10,14-hexadecatetraen-1-o l, said compound being in substantially pure form.
(E,E,E,E), (E,Z,E,E), (E,E,Z,E) and (E,Z,Z,E)-7-Hydroxy-methyl-3,11,15,19-tetramethyl-2,6,10,14,18-eicosapenta en-1-ol, said compound being in substantially pure form.
Dependencies are inferred from the claim text.